Emerging drugs for chronic constipation

Michael D. Crowell, Lucinda A. Harris, Tisha N. Lunsford, John K. DiBaise

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


Chronic constipation (CC) is one of the most common functional gastrointestinal disorders. CC is estimated to affect up to 27% of the North American population. Although not life-threatening, CC can have profoundly negatively affects on quality of life and result in significant economic burden in terms of both direct and indirect healthcare costs. Possible etiologies for CC include alterations in gastrointestinal motility and secretion. Research efforts in CC have begun to identify multifactorial and often overlapping etiologies including abnormalities in myenteric neurons, alterations in neurotransmitters and their receptors, and incoordination of the muscles of the pelvic floor or anorectum. CC may be influenced by genetic predisposition, environmental factors and stress. In this article, the safety and efficacy of traditional and emerging therapies for CC are examined.

Original languageEnglish (US)
Pages (from-to)493-504
Number of pages12
JournalExpert Opinion on Emerging Drugs
Issue number3
StatePublished - Sep 2009


  • Chronic constipation
  • Drugs
  • Functional
  • Irritable bowel syndrome
  • Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Emerging drugs for chronic constipation'. Together they form a unique fingerprint.

Cite this